VivoSeq
Oncology

Nodal Marginal Zone B-Cell Lymphoma

2

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Nodal Marginal Zone B-Cell Lymphoma is an early-stage landscape with 2 programs across 2 companies. The most active players are TG Therapeutics, Inc., Beijing InnoCare Pharma Tech Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

T

TG Therapeutics, Inc.

1 program

Phase 1B

Beijing InnoCare Pharma Tech Co., Ltd.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

Ublituximab

TG Therapeutics, Inc.

Phase 21

Orelabrutinib

Beijing InnoCare Pharma Tech Co., Ltd.

Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

2programs
Small molecule150%
Monoclonal antibody150%

Modality classified for 100% of 2 pipeline programs.

Analysis

Trial Status

1

clinical trials

Recruiting1 · 100%

Clinical Trials

Trial Activity

The Treatment of Ocular Adnexal Extranodal Marginal Zone B-cell Lymphoma by Orelabrutinib and Radiotherapy
Recruiting·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT06503276·50 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)